Physiological and pathological roles of Hic-5 in several organs (Review)

SHUN YAO1*, ZHEN TU2*, XINGYUE YANG1, LI ZHANG1, YULING ZHONG1, LIMING ZHENG1, HUI WANG1, ZHIQIANG YI1, JIAXING AN1, HAI JIN1, GUORONG WEN1 and BIGUANG TUO1,3

1Department of Gastroenterology, Digestive Disease Hospital, Affiliated Hospital of Zunyi Medical University, Zunyi, Guizhou 563003; 2Department of Urological Surgery, People's Hospital of Yuechi County, Guang'an, Sichuan 638300; 3The Collaborative Innovation Center of Tissue Damage Repair and Regenerative Medicine of Zunyi Medical University, Zunyi, Guizhou 563003, P.R. China

Correspondence to: Professor Biguang Tuo, Department of Gastroenterology, Digestive Disease Hospital, Affiliated Hospital of Zunyi Medical University, 149 Dalian Road, Huichuan, Zunyi, Guizhou 563003, P.R. China
E-mail: tuobiguang@aliyun.com

*Contributed equally

Key words: hydrogen peroxide-inducible clone 5, focal adhesion sites, physiological function, pathological function

Received July 12, 2022; Accepted September 21, 2022

DOI: 10.3892/ijmm.2022.5194

Abstract. Integrins allow cells to adhere to the extracellular matrix and promote the recruitment of other integrins, resulting in the formation of focal adhesion sites at the binding sites. Focal adhesion sites play essential roles in the assembly of the cytoskeleton and are vital in shaping the structure of cells. They also play other regulatory roles by influencing numerous biological functions, such as cell proliferation and apoptosis. Hydrogen peroxide-inducible clone 5 (Hic-5) is a member of the Paxillin family of proteins and is an adhesive plaque scaffolding protein. Its expression can be detected in both vascular and smooth muscle cells. Thus, it plays an essential role in vascular remodeling, as well as in fibrotic diseases. Hic-5 functions as a coactivator of steroid receptors, thus playing a role in steroid hormone-dependent diseases. It also plays a vital role in the invasive metastasis of various types of cancer. Moreover, several studies have demonstrated that Hic-5 plays a critical role in transcriptional regulation, as well as in numerous signaling pathways. Therefore, the inhibition of the functions of Hic-5 may prevent the development or halt the progression of several diseases. Its use as a therapeutic target in future investigations may thus aid in the treatment of several diseases, including various types of cancer. The present review article focused on the expression and functions of Hic-5 in different organs, with the aim of highlighting novel possibilities for future research.

Contents

1. Introduction
2. Structure and function of Hic-5
3. Hic-5 and the regulation of signaling pathways
4. Role of Hic-5 in the cardiovascular system
5. Role of Hic-5 in the digestive system
6. Hic-5 and the urinary system
7. Hic-5 and tumors
8. Hic-5 and other diseases
9. Perspectives of Hic-5 in clinical applications
10. Conclusions

1. Introduction

Hydrogen peroxide-inducible clone 5 (Hic-5) was isolated from a transforming growth factor-β (TGF-β) or hydrogen peroxide-inducible gene clone by ablative hybridization in 1994 by Shibanuma et al (1). Subsequently, after studying Hic-5 at the molecular and cellular level, it was found that Hic-5 is a homolog of Paxillin and is currently considered a member of the Paxillin protein family (2). The Paxillin family includes Paxillin, Leupaxin and Hic-5, and they function as molecular adapters that deliver signals when the cellular adhesion environment changes (2).

Hic-5 has a high degree of homology with Paxillin and its intracellular localization is similar (Table I) (2-19). It is primarily restricted to focal adhesion sites, and sites of adhesion with the extracellular matrix (ECM) via integrins (2). In contrast to the abnormal development of extra-embryonic tissues, and the segmentation of the heart and body in mouse fetuses following the knockout of Paxillin in mice (20), no effects on homeostasis and development were observed in Hic-5 knockout mice (13). This indicates that Hic-5 is not required for development, and suggests that Paxillin and Hic-5 have different physiological functions. Hic-5 expression has been detected in smooth muscle cells (SMCs) of various tissues (21), and a higher level of expression has been observed in the lungs and spleen (1). Hic-5 expression has been assessed and shown to vary in several cell lines (2). It is highly expressed...
in mesenchymal cell lines, such as fibroblasts, whilst it exhibits lower levels of expression in epithelial cell lines (2). The fact that Hic-5 expression can be detected in different tissues and cells also implies that it plays a central role in the pathophysiology of different organs.

However, the physiological and pathological roles of Hic-5 have not yet been systematically clarified. Therefore, the present review summarized the expression of Hic-5 in different organs and its role in various diseases.

2. Structure and function of Hic-5

Hic-5 has a molecular weight of 55 kDa and consists of 444 amino acids; its gene is located in chromosome 16p11 in humans and in chromosome 7 mice (3). A long intron can be found in the genetic structure of Hic-5 between the N-terminal and C-terminal structural domains (22). Hic-5 consists of four Leu- and Asp-rich LD domains in the N-terminal region; LD1 is missing in one isoform; and there are four LiM domains with two zinc fingers in the C-terminal region (2). Hic-5 also includes multiple phosphorylation sites; tyrosine phosphorylation can occur in response to stimuli, such as osmotic pressure, serum factors, lysophosphatidic acid (LPA) and endothelin (8,23), which further regulate signaling associated with lamellar pseudopodia formation to influence cell motility (24). The structural domains involved in protein interactions include the LD and LiM structural domains, and these allow Hic-5 to function as a junction molecule and thus facilitate protein-protein interactions. It can also serve as a docking site for signaling proteins, such as vinculin and focal adhesion kinase (FAK) (25,26). Additionally, Hic-5 can function as a linker molecule in the integrin substrate complex and can modulate integrin signaling through interactions with binding molecules (2). Under normal culture conditions, the majority of cellular behaviors are almost unaffected by Hic-5 expression (2). When healthy adhesion maintenance is compromised under conditions of stress that affect focal adhesion sites, Hic-5 may inhibit adhesion and excessive changes in cytoskeletal structure by antagonizing Paxillin (21,27).

There is a nuclear export signal (NES) that overlaps with the amino-terminal LD structural domain, and this allows Hic-5 to enter the nucleus from the cytoplasm via an oxidation-sensitive NES (28). Hic-5 is transferred from a focal adhesion site to actin stress fibers in the presence of organic stress, thereby regulating cell contractility (21). In various pathophysiological processes, Hic-5 functions primarily through two different pathways. First, it can affect the transcriptional levels of several nuclear receptors (29), including the glucocorticoid receptor (GR) (4,30), the androgen receptor (AR) (31) and the progesterone receptor (13). Hic-5 may affect the genomic occupancy of GR, as well as the assembly of transcriptional complexes and may thus function as a glucocorticoid regulatory switch for several genes (30). After entering the nucleus, Hic-5 can regulate the expression of several genes through transcriptional regulation (4-6). For example, it can repress Lef/Tcf-driven transcription. Multiple sequences upstream of c-fos (such as GC/Sp1 and Ets, amongst others) can activate Hic-5 (Fig. 1) (5). The P21 promoter region can also respond to Hic-5 in the nucleus, which can bind to Sp1, Smad3, and p300 to create a transcriptional complex (6). Hic-5 also interacts with glucocorticoid response promoters (such as TIF-2 and p300, among others) and coactivators, and thus functions as a steroid receptor coactivator (6,32-34). In addition, Hic-5 acts in conjunction with various structural and signaling molecules (such as FAK, vinculin and PIP-PEST, amongst others) to form a scaffold for integrin signaling (Fig. 2) (8-10,14). Hic-5 has been shown to be essential to the adhesion formation of the three-dimensional (3D) structure of the ECM (35). Moreover, when Hic-5 expression is low, fibroblasts exhibit higher migratory capacity, and when its expression is high, the migratory capacity of fibroblasts is reduced and the contractile capacity is increased, increasing the contraction and matrix remodeling of the ECM (36). This allows Hic-5 to function as a key factor in various types of fibrotic diseases (7,11,37).

3. Hic-5 and the regulation of signaling pathways

A main mechanism through which Hic-5 exerts its effects is via the activation of various signaling pathways (Fig. 3). It can induce the formation of abdominal aortic aneurysm (AAA) by promoting the activity of the JNK pathway (38). The TGF-β/Smad pathway is a crucial factor in fibrotic diseases (39,40), and TGF-β can promote Hic-5 expression (1). Previous studies have also demonstrated that Hic-5 can promote the development of liver fibrosis and pancreatic fibrosis via the activation of Smad2/Smad3 and inhibition of Smad7 (7,41). It also inhibits the apoptosis of prostate cancer cells by binding and interacting with Smad1 (42). Hic-5 inhibits β-catenin function upon interaction with Smad4, thereby promoting the proliferation and inhibiting apoptosis of osteosarcoma (OS) cells (43). Hic-5 can also promote inflammation by activating the activity of the NF-kB pathway (44) and can promote cell apoptosis through the Toll-like receptor 4 (TLR4)/Fas-associated protein with death domain (FADD) signaling pathway (45). Hic-5 can promote hepatocarcinogenesis by activating the reactive oxygen species (ROS)/JNK pathway (46), while in a variety of tumors, Hic-5 can induce epithelial-mesenchymal transition (EMT) by activating RhoA/ROCK I signaling, thus promoting invasion and metastasis (12,47,48). Hic-5 may play a critical role in other signaling pathways; however, current research is limited, and further research is required to elucidate the roles of Hic-5 in other signaling pathways.

4. Role of Hic-5 in the cardiovascular system

A high expression of Hic-5 has been detected in both vascular and visceral SMCs in mice and humans (49); under physiological conditions, Hic-5 expression has been shown to play a very limited role in intravascular homeostasis (13). Moreover, it has been demonstrated Hic-5-/- mice do not exhibit any notable abnormalities compared with the wild-type mice in terms of arterial structure and function (3). However, other researchers have found a reduced endothelial cell (EC) expansion in capillaries and an impaired structural organization of cells on basement membrane extracts following the knockdown of Hic-5 (50). Hic-5 has also been found to be expressed in mouse ECs, which are involved in both EC spreading and migration (3). In ECs, the knockdown of Hic-5 has been found to reduce EC sprouting and lumen formation, whereas the sprouting deficiency is restored upon the
re-expression of Hic-5. Hic-5 can interact with membrane type-1 matrix metalloproteinase (MT1-MMPs) under the stimulation of pro-angiogenic factors (51). During EC sprouting, the expression of MT1-MMPs and Hic-5 complexes increases, and this promotes the formation of MT1-MMPs and FAK complexes, thus playing a role in EC matrix proteolysis and cell motility (51). All types of vessels contain ECs and vascular SMCs (VSMCs); this suggests that Hic-5 functions as an essential factor in all types of vascular diseases.

Hic-5 and vascular injury. A previous study on Hic-5 found that it carried out a regulatory function in the activation of integrin αIIbβ3 and platelet aggregation in mice (52). However, a subsequent study found that the knockdown of Hic-5 did not affect hemostasis and experimental thrombosis (53), possibly as the function affected by Hic-5 absence was compensated for by Paxillin and Leupaxin, which are also expressed in mouse platelets (54).

In a previous study, in a rat model of wire-mediated femoral artery injury, the expression of Hic-5 was significantly downregulated after 4 days, followed by a gradual recovery to normal levels after 2 weeks, suggesting that Hic-5 expression is downregulated during the acute phase of vascular injury (13). By contrast, in Hic-5−/− mice, a significant reduction in the arterial mesangial area with vascular injury was observed along with the accelerated formation of neointima and promotion of chronic apoptosis of VSMCs (13). Similarly, in another study, in the mouse SM SV30 cell line, the expression of Hic-5 was notably increased after differentiation above undifferentiated levels, and furthermore, in a rat model of acute vascular injury following the local delivery of Hic-5 using an adenoviral vector, neointima formation was inhibited, primarily by reducing the migration of vascular SM cells (55). However, further investigations are required to explore the specific underlying mechanisms.

Hic-5 and atherosclerosis. The adhesion of monocytes and ECs is a key factor in the development of atherosclerotic plaques (56,57). The APOE−/− model is currently the most well-recognized and widely used model for studying atherosclerosis. Arita-Osakow et al (58) extracted the aortas of APOE−/− and LDLR−/− mice and found that Hic-5 deficiency inhibited the adhesion of THP-1 monocytes to the aorta typically stimulated with TNF-α or oxidized low-density lipoprotein. Electron microscopic analysis of aortas extracted from APOE−/− mice revealed that Hic-5 deletion significantly inhibited TNF-α-induced microvilli-like structures. Further experiments revealed that the knockdown of Hic-5 significantly inhibited atherosclerotic changes in mice. The same reduction in the number of surface microvillus-like structures was found in human umbilical vein ECs (HUVECs) in which Hic-5 was knocked down, while the number of surface microvillus-like structures was significantly increased in HUVECs after overexpression of Hic-5 (58). These findings indicate that Hic-5 in ECs not only promotes the formation of microvillous-like structures, but also promotes the recruitment of monocytes, which ultimately leads to atherosclerosis (58). However, the exact role of Hic-5 has not yet been determined, thus the mechanisms through which Hic-5 affects atherosclerosis warrant further investigations in future studies.

| Table 1. Characterization and expression of Paxillin and Hic-5. |
|-------------------|-------------------|-------------------|-------------------|-------------------|
| **Protein**       | **Molecular weight (kDa)** | **Chromosome**    | **Domain structure** | **Expressing tissues or cells** |
| Hic-5             | 55                 | 16p11 (human)     | Four LD motifs      | Widespread high level of expression in SMcs, platelets, and fibroblasts, etc. |
| Paxillin          | 68                 | 12q24.2 (human)   | Four LIM domains    | Universally expressed |
| **Functions**     | **Related disease** | **Expressing tissues or cells** | **Domain structure** | **Expressing tissues or cells** |
| Hic-5 had regulatory function in the activation of integrin αIIbβ3 and platelet aggregation in mice (52). | Vascular injury, fibrosis, cancer, etc. | Widespread high level of expression in SMcs, platelets, and fibroblasts, etc. |
| Hic-5 was notably increased after differentiation above undifferentiated levels, and furthermore, in a rat model of acute vascular injury following the local delivery of Hic-5 using an adenoviral vector, neointima formation was inhibited, primarily by reducing the migration of vascular SM cells (55). | | Universally expressed |
| Hic-5, hydrogen peroxide-inducible clone 5. | | | | |
Figure 1. Hic-5 as a transcriptional co-activator. GC/Spl, Ets and ERE/AP-1 interact with Hic-5 to activate c-fos. Spl, Smad3, and p300 interact with Hic-5 to activate p21. TIF-2, RAC3, CBP, and p300 interact with Hic-5 to activate GR. Hic-5 can repress Lef/Tcf transcription. Hic-5, hydrogen peroxide-inducible clone 5.

Figure 2. Hic-5 functions as an adaptor for recruitment of several signaling molecules, including FAK, Talin, vinculin, Csk, GIT1 and PTP-PEST. Hic-5, hydrogen peroxide-induced clone 5; Csk, C-terminal Src kinase; GIT1, G protein-coupled receptor kinase interacting ArfGAP 1; PTP-PEST, protein-tyrosine phosphatase PEST.
Hic-5 and AAA. In a previous study in which models of AAA were constructed by the administration of angiotensin II in APOE<sup>−/−</sup> and APOE<sup>−/−</sup> Hic-5<sup>−/−</sup> mice, it was found that Hic-5<sup>−/−</sup> mice exhibited a significantly lower degree of AAA and had smaller maximum aortic diameters (38). Abdominal artery rupture and mass hemorrhaging were observed in the APOE<sup>−/−</sup> mice, but not in the APOE<sup>−/−</sup> Hic-5<sup>−/−</sup> mice, indicating that the knock-down of Hic-5 prevented AAA formation and rupture (38). Further mechanistic analyses revealed that Hic-5 promoted the activation of the JNK pathway, subsequently increasing MMP expression and promoting the development of AAAs (38).

Hic-5 and hypertrophic heart disease. Hic-5 has also been shown to be expressed in neonatal rat ventricular myocytes (NRVMs) (59). In NRVMs, epinephrine induced the expression of Hic-5, and Hic-5 overexpression significantly increased the number of cells with organized cytoskeleton (59). Mechanistically, Hic-5 exerted its effects via regulation of the ERK1/2 signaling pathway (59). Increased levels of Hic-5 were found in a mouse model of hypertrophic heart disease established using thoracic aortic constriction (59). However, the elevated of Hic-5 in the model alone did not suggest that it played a role in the development of hypertrophic heart disease; thus, future investigations are required to determine its role in hypertrophic heart disease.

5. Role of Hic-5 in the digestive system

Hic-5 and the liver

Hic-5 and liver fibrosis. Previous studies have demonstrated that Hic-5 is not expressed in quiescent hepatic stellate cells (HSCs), although its expression is significantly increased following HSC activation (7,60). The significant upregulation of Hic-5 expression has also been found in liver tissues from patients with fibrosis, or in mice subjected to bile duct ligation or mice with CCl<sub>4</sub>-induced mouse liver fibrosis, as well as in activated HSCs (7). It has been revealed that HSCs from Hic-5<sup>−/−</sup> mice exhibit a significantly reduced activation when cultured (7). Additionally, Hic-5 has been found to promote fibrosis by activating the TGF-β/Smad2 pathway, while inhibiting Smad7 (7).

Hic-5 and hepatic ischemia-reperfusion injury (HIRI). In a previous study, Hic-5 expression was shown to be increased in models of HIRI, and the expression of inflammatory chemokines was found to be decreased in a Hic-5<sup>−/−</sup> HIRI mouse model, while the extent of liver injury was found to be reduced compared with wild-type mice (45). Further experiments revealed that Hic-5 activated the NF-κB signaling pathway to enhance the inflammatory response, and activated the TLR4/FADD pathway to increase hepatocyte apoptosis, which...
ultimately led to the exacerbation of the lesions in mice (45). This suggests that Hic-5 targeted therapy may be beneficial for liver transplantation-induced HIRI. Similarly, Hic-5 may play a role in ischemia-reperfusion injury in other organs (such as the lungs); however, further studies are required to confirm this.

**Hic-5 and chronic pancreatitis (CP).** Similar to liver fibrosis, pancreatic fibrosis is also primarily caused by the activation of pancreatic stellate cells (PSCs) (61). A high expression of Hic-5 was likewise found in pancreatic tissues of patients with CP and was primarily expressed in activated PSCs (41). In a previous study, by culturing pancreatic primary PSCs, it was found that the knockdown of Hic-5 inhibited PSC activation. The same study subsequently found a significant attenuation of pancreatic fibrosis in Hic-5−/− mice in a model of caerulein-induced CP, suggesting that Hic-5 can promote the development of CP (41). By culturing primary PSCs, Hic-5 was shown to increase the activation of PSCs by increasing the phosphorylation of Smad2, ultimately promoting the development of CP (41). Another study also found that the knockdown of Hic-5 inhibited NF-κB/p65 expression (44). This also suggested that Hic-5 can be used as a diagnostic marker and a potential therapeutic target in CP.

6. **Hic-5 and the urinary system**

**Hic-5 and the kidneys.** In rat kidneys, Hic-5 expression has been detected in mesenchymal cells, mesangial cells and ECs (62). This suggests that Hic-5 may be involved in the development of glomerulosclerosis (11). Another study also demonstrated that the increased expression of Hic-5 in glomerular mesangial cells was not dependent on the TGF-β-induced pro-sclerotic phenotype (63); however, that study only illustrated the increased expression of Hic-5 in glomerulosclerosis, which does not yet indicate a role in the development of glomerulosclerosis, and therefore further studies are required to determine this.

**Hic-5 in the prostate.** Previous research detected Hic-5 expression in the normal prostate mesenchyme and exhibited a lesser reduction in the tumor-associated mesenchyme (31). Hic-5 expression was subsequently found in both the normal and tumor prostate epithelium, as well as in prostate cancer cells and prostate cancer tissues (42,64,65). Hic-5 regulates the transcription of AR (31). When steroid ligands are absent, Hic-5 can interact with nuclear receptor co-blockers to inhibit transcription (34,66). In prostate myofibroblasts, Hic-5 rapidly translocates to the nucleus in response to the action of androgens, consistent with the increased phosphorylation of adherent spot kinase. Hic-5 acts as a co-regulator and AR can lead to androgen-induced transcriptional enhancement through interaction with the coactivator, Hic-5:AR/ARA55, thereby affecting androgenic effects on growth, cell adhesion, motility and invasion regulation (67). It was similarly found that the mRNA levels of Hic-5:AR/ARA55 in normal or benign prostate hypertrophy tissues were reduced in hormone-independent prostate cancer tissues (12,64); in normal prostate tissues, it was primarily expressed in the interstitium (31,68), and in prostate cancer tissues it was also expressed in the interstitium. Hic-5:AR/ARA55 was also observed in the cytoplasm and focal adhesion sites of the prostate mesenchymal cell line, WPMY-1 (31). Hic-5:AR/ARA55 activates AR activity by interacting with the endogenous androgen response promoter (31). CYP24A1 encodes the 1,25D3 metabolizing enzyme 24-hydroxylase (69). Hic-5 is a coactivator of the vitamin D3 receptor (VDR) and can limit the negative feedback circuit of VDR activity by participating in VDR-mediated transcription of CYP24A1 (69).

7. **Hic-5 and tumors**

Tumor cells exhibit two interchangeable patterns of cell movement, mesenchymal or amoeboid; during invasion, tumor cells can migrate to different 3D microenvironments through these two switchable motility modes, and this allows them to invade the tumor stroma and circulatory system (35,70). Gulvady et al (71) found that the expression levels of Hic-5 varied greatly by analyzing the expression of Paxillin and Hic-5 in a variety of tumor cells, while the levels of Paxillin were relatively stable. It was also found that cancer cell lines with low Hic-5:Paxillin ratios lacked the ability to efficiently convert to a mesenchymal phenotype, while cell lines with a high Hic-5:Paxillin ratios were able to adequately switch from an amoeboidal to a mesenchymal phenotype. In a variety of tumors, Hic-5 has been shown to induce EMT by activating Rhoa/ROCK I signaling, thus promoting invasion and metastasis (12,47,48), which highlights its potential as a biomarker for metastasis in several tumors and as a therapeutic target.

**Hic-5 and hepatocellular carcinoma (HCC).** Hic-5 is also involved in HCC progression. The upregulation of proline-rich tyrosine kinase 2 (Pyk2) is expressed in HCC liver tissues and is associated with a worse prognosis (72). Other studies have demonstrated that Pyk2 upregulates the activation and localization of Hic-5 (73). In another study, Wu et al (46) found that Hic-5 expression was upregulated in HCC cell lines that originated from high motility cancers, but not in HCC cells originated from low motility cancers when they analyzed liver tissues from patients with HCC, suggesting that its overexpression was closely associated with the metastasis of HCC. This suggests that Hic-5 may be used as a biomarker for metastasis in with HCC. The same authors also found that the knockdown of Hic-5 in high motility-derived HCC cells significantly reduced the invasive ability of HCC cells (46). Further analyses revealed that Hic-5 affected HCC progression through the ROS/JNK pathway (46). However, that study was limited to assessing the progression of HCC in vitro, and further studies are thus required to confirm its role in vivo and to elucidate the specific underlying mechanisms.

**Hic-5 and pancreatic cancer (PC).** In a previous study, the upregulated expression of Hic-5 was detected in PC, and the knockdown of Hic-5 revealed that PC cell (PCC) proliferation was suppressed and apoptosis was increased, while PCC invasion and migration were reduced (74). The same study also found that patients with a high expression of Hic-5 in PC had lower survival rates (74). However, there are fewer studies investigating the role of Hic-5 in PC; thus, further cellular and animal models are required to examine the mechanisms through which Hic-5 specifically affects PC and to identify novel strategies for the management of PC.
**Hic-5 and esophageal cancer.** The tumor microenvironment plays an essential role in tumor development and metastasis (75); cancer-associated fibroblasts (CAFs) are an important component of the tumor microenvironment (76) that release cytokines into the ECM, thereby promoting circulating tumor metastasis (77,78). In a previous study, the high expression of Hic-5 was detected in the CAFs of esophageal squamous cell carcinoma (ESCC) (79). That study further demonstrated that the invasion and migration of cells was inhibited following the knockdown of Hic-5 in KYSE150/TE1 esophageal cancer cells co-cultured with CAFs (79). RNA-seq revealed that Hic-5 in CAFs may promote tumor progression by regulating cytokines (such as CCL2) and altering the ECM (79). The same study also found an association with esophageal cancer lymph node metastasis through survival analysis (79). This suggests that the levels of Hic-5 may be used as a marker of lymph node metastasis in ESCC. The effect of Hic-5 on the biological behavior of esophageal cancer cells has only been demonstrated in vitro; thus, *in vivo* models are warranted to explore the role of Hic-5 and its specific mechanisms of action in esophageal cancer.

**Hic-5 and colon cancer.** PPARγ is a major regulator of adipocyte differentiation (80). Hic-5 has been shown to bind to and activate PPARγ, and both Hic-5 and PPARγ are expressed in normal and malignant intestines (33). In a mouse colon cancer model, the expression of both PPARγ and Hic-5 has been found to be notably decreased (33). Hic-5 has also been found to enhance PPARγ-mediated epithelial gene induction in colon cancer cells (33).

The high expression of Hic-5 was also previously detected in CAFs of tumor tissues from patients with colon cancer (81). The addition of CAF supernatant to normal fibroblasts induced the expression of Hic-5 (81). Following the establishment of a mouse colon tumor model by azoxymethane induction, no tumors were found in Hic-5-/- mice compared with wild-type mice, where tumors were found in 55% of mice after 20 weeks; proliferative polyps were found in only one location after 24 weeks, and advanced adenocarcinomas was only observed in wild-type mice (81). Further analyses revealed that HIC-5 induced lysyl oxidase (LOX) expression following nucleation, and LOX promoted the cross-linking of collagen fibers and thus increased the stiffness of ECM, which eventually promoted tumor progression (81). This suggests that Hic-5 may serve as a therapeutic target for the management of colon cancer.

**Hic-5 and prostate cancer.** Previous research has shown that Hic-5 can interact with Smad1 to inhibit the apoptosis of prostate cancer cells (42). LNCaP is a prostate epithelial cell line that does not express Hic-5. Hic-5 overexpression using lentiviral transfection and subsequent administration in mice has been shown to result in the inhibition of tumor growth (64). Further mechanistic research has revealed that HIC-5/ARA55 can inhibit c-Myc expression in an androgen-dependent manner (65). The expression of c-Myc is increased when deprived of androgens, and Hic-5/ARA55 also inhibits c-Myc expression by suppressing it in a TCF4-dependent and non-dependent manner (64).

Hic-5 could interact with 1,25D3 to inhibit prostate cancer cell proliferation. Following androgen deprivation, Hic-5 induces different responses in prostate tumors to 1,25D3, particularly during androgen deprivation therapy (69). Hic-5 can play a differential role in the adjuvant treatment of VDR activity in prostate cancer. This suggests that patients with prostate cancer with a downregulated expression of Hic-5 may benefit more from treatment with VDR ligands (69).

**Hic-5 and breast cancer.** Gulvady *et al* (71) found that the expression of Hic-5 in breast cancer cells was upregulated. They further constructed a mouse polyoma middle T-antigen breast cancer model and found that CAFs in Hic-5-/- mice could not effectively form fibrillar adhesion in both 2D and 3D (82). Using bioinformatics analysis, it was found that the high expression of Hic-5 in patients with breast cancer was negatively associated with the distant metastasis-free survival (DMFS) of patients (83).

**Hic-5 and ovarian cancer.** The high expression of Hic-5 was previously found in advanced ovarian cancer, and EMT independent of TGFβ-1 was induced by the overexpression of Hic-5 in the ovarian cancer cell line, A2780 (which is typically morphologically epithelial), accompanied with enhanced cell proliferation and migratory/invasive ability, as well as increased resistance to chemotherapeutic agents (48). In addition, in epithelial ovarian cancer cells, the knockdown of Hic-5 inhibited its proliferation, migration/invasion and induced mesenchymal-epithelial transition, and it was further shown that it may promote EMT in ovarian cancer via the regulation of the RhoA/ROCK signaling pathway (48). However, further *in vivo* studies are required to investigate the role of Hic-5 in ovarian cancer.

**Hic-5 and osteosarcoma (OS).** The high expression of Hic-5 was previously detected in both OS tissues and cells, and a higher percentage of low-grade OS tissues exhibited an upregulated expression of Hic-5 (46.7%), while its expression was reduced in the majority of high-grade OS patient tissues (53.3%) (43). The knockdown of Hic-5 suppressed the proliferation of OS cells, whereas it promoted apoptosis. Additionally, it was found that Hic-5 expression in exosomes was similarly reduced following the knockdown of Hic-5, and it was further found that Hic-5 interacted with Smad4 through the exosomal pathway to promote the activation of β-catenin, thus promoting the proliferation of OS cells (43).

**Hic-5 and melanoma.** Hic-5 expression was previously detected in both human melanoma cells and murine B16-F1 cells (84). The knockdown of Hic-5 in murine melanoma B16-F1 cells was shown to result in reduced cell proliferation and migration, and significantly inhibited tumor growth and lung metastasis in further subcutaneous tumorigenesis assays in mice (84). It was also found an increase in RhoA activity upon the knockdown of Hic-5, accompanied by an altered amoeboid-like phenotype, leading to a loss of cell plasticity, which may also be responsible for its effect on cell motility (84). This suggests that Hic-5 may influence melanoma development via modulation of the RhoA/ROCK signaling pathway.

8. **Hic-5 and other diseases**

**Hic-5 and Alzheimer's disease (AD).** In a previous study using a model AD, an increased expression of Hic-5 was detected...
in pyramidal neurons in the CA1 region of the hippocampus (85). It is possible that Hic-5-mediated intracellular signaling in the ECM is involved in the pathogenesis of AD. However, to the best of our knowledge, no further studies have been performed to date to confirm whether Hic-5 is involved in AD development, and thus further research is required to determine this.

**Hic-5 and osteoarthritis.** A mouse model of osteoarthritis of the knee was previously established by surgical induction, and a significantly lower degree of cartilage degradation was observed in Hic-5−/− mice than in wild-type mice after 8 weeks (86). Furthermore, by extracting primary chondrocyte cultures, it was found that Hic-5 promoted the development of osteoarthritis primarily by promoting the expression of inflammatory cytokines, or mechanical load-induced MMP13, and a disintegrin and metalloproteinase with thrombospondin type 1 motif 5 (86).

**Hic-5 and skin.** Hic-5 modulates androgen sensitivity in hair follicle papillae (87), while in scar-forming myofibroblasts, autocrine TGF-β upregulates Hic-5 expression, further downregulating the autocrine loop of Hic-5 and collagen synthesis (88). The overexpression of Hic-5 in keloid-derived fibroblasts was previously found to increase collagen expression in keloid scars (89). Similarly, Hic-5 was confirmed to be expressed in keloid specimens (8/15) using immunohistochemistry, and was not observed in normal tissues; its expression was shown to be primarily localized in the nucleus where it stimulated Smad2/3 expression via other pathways (89). Hic-5 expression was found to be increased in patients with systemic sclerosis (SSc) and SSc dermal fibroblasts. In addition, in SSc fibroblasts, the knockdown of Hic-5 reduced the production of type I collagen by >50%. This suggests that Hic-5 can promote the formation of fibrosis in SSc, indicating that it may be a therapeutic target for the management of SSc fibrosis (90). However, that study had a small clinical sample; thus, further clinical samples are warranted to confirm these findings and the underlying molecular mechanism need to be assessed.

**Hic-5 and the eyes.** Aqueous humor (AH) homeostasis is critical for maintaining normal intraocular pressure (91). By contrast, increased obstruction or resistance to the atrial fluid flow through the trabecular meshwork (TM) causes increased intraocular pressure and is a major risk element for primary intraocular pressure elevation (92). In a previous study, in human TM (HTM) cells, Hic-5 expression was limited to the focal adhesion of HTM cells, as well as throughout the TM and AH efflux pathways of the Schlemm’s canal; the administration of recombinant Hic-5 was found to result in the redistribution of actin stress fibers, focal adhesion and αv integrins in the focal adhesion, along with an increase in a-SMA, and increased collagen-1 expression, whereas the knockdown of Hic-5 reversed these effects. In the presence of dexamethasone, Hic-5 in TM increased resistance to AH efflux via the trabecular pathway, which suggests that Hic-5 plays a critical role in regulating eye AH outflow through the TM (93).

**9. Perspectives of Hic-5 in clinical applications**

TGF-β plays a key role in the progression of various diseases. Hic-5 expression can be induced by TGF-β, plays a key role in various diseases (Table II) (7,11,13,31,38,41-46,48,55,58-60, 64,71,74,79,81,83-86,90,94-122) and the negative effects of its knockdown are limited and not severe; thus, targeting Hic-5 may be a suitable approach for the management of several diseases. Hic-5 expression was previously found to be significantly elevated in liver fibrosis, pancreatic fibrosis, HIRI, glomerulosclerosis and SSC, while disease pathology was reduced following the knockdown of Hic-5 (7,11,41,44,45,88,90), which also suggests its potential use as a biomarker for the diagnosis of fibrotic diseases and as a potential therapeutic target. The role of Hic-5 in other fibrotic diseases likely promotes fibrosis via the activation of the TGF-β/Smad pathway.

In tumors, the high expression of Hic-5 was found to promote the transformation of tumor cells with an amoeboïd phenotype to a mesenchymal phenotype and promote EMT through the RhoA/ROCK pathway, thus promoting tumor cell plasticity and invasiveness (12,47,48), which also suggests that Hic-5 may be used as a biomarker for tumor metastasis. Related studies have demonstrated that Hic-5 expression is upregulated in HCC with a low migratory capacity and is also associated with lymph node metastasis in patients with esophageal cancer (46,79). Therefore, it may be used as a biomarker for the detection of metastases in patients with HCC, and lymph node metastases in patients with esophageal cancer. It is also negatively associated with the survival of with PC and the DMFS of patients with breast cancer and may serve as a biomarker for predicting a poor prognosis of patients with PC and breast cancer. The knockdown of Hic-5 in HCC cells, PC cells, esophageal cancer cells, ovarian cancer, melanoma and cholangiocarcinoma cells led to the inhibition of tumor cell invasion and migration (43,46,48,74,79,84,123), and the knockdown of Hic-5 in HuCCT1 cholangiocarcinoma cells was also found to inhibit cholangiocarcinoma migration in a concentration-dependent manner (123). This suggests that it may be possible to inhibit tumor metastasis in these tumors by targeting Hic-5. However, the effects of the knockdown of Hic-5 were only verified at the cellular level in these tumors, and further *in vivo* experiments are thus required to confirm these results. In addition, the knockdown of Hic-5 was previously found to suppress tumorigenesis in mouse models of colon and breast cancer (81,82). In patients with PC, those with a downregulated HIC-5 expression were found to benefit more from VDR ligand therapy (69). Furthermore, the majority of research has focused on the effects of Hic-5 on tumor metastasis, and thus further studies are required to explore the effects of Hic-5 on tumorigenesis.

In future studies, drugs targeting Hic-5 need to be investigated, which may provide novel options for the treatment of tumors. Moreover, Hic-5 promotes CAF protolifer adhesion by direct interaction with Tensin1, and the interaction is through a phosphorylation-dependent mechanism (83). Therefore, Hic-5 plays a key role in CAFs, and future research on drugs targeting the tumor microenvironment using Hic-5 as a target may provide novel avenues for the management and treatment of several types of cancer.
| Disease                        | Hic-5                                                                 | TGF-β                                                                 | (Refs.) |
|-------------------------------|----------------------------------------------------------------------|----------------------------------------------------------------------|---------|
| Vascular injury               | • Expression was downregulated during the acute phase of vascular injury. Hic-5⁺ mice exhibited a significant reduction in the arterial mesangial area as well as accelerated neonatal intima formation and increased levels of chronic apoptosis of vascular SMCs. | • Increased expression after vascular injury.                        | (13,55,94,95) |
|                               | • Hic-5⁻/⁻ mice exhibited a significant reduction in the arterial mesangial area as well as accelerated neonatal intima formation and increased levels of chronic apoptosis of vascular SMCs. | • Promotes the proliferation of neoplastic endothelium.                |         |
| Atherosclerosis               | • Plays an essential role in the formation of microvillous structures of endothelial cells. | • Decreased TGF-β levels in patients with advanced atherosclerosis.  | (58,95,96) |
|                               | • Promotes atherosclerosis by recruiting monocytes and interacting with monocytes. | • Promotes the development of atherosclerosis.                        |         |
| Abdominal aortic aneurysm     | • Activates the JNK pathway to enhance MMP expression in VSMCs and promote AAA formation. | • Decrease aneurysm formation and progression.                        | (38,96,97) |
| Hypertrophic heart disease    | • Overexpression of Hic-5 increases the number of cells in the cytoskeletal tissue. | • Not reported                                                      | (59)    |
| Liver fibrosis                | • Expression is upregulated in patients with liver fibrosis and in mouse models. | • Activation of hepatic stellate cells through the TGF-β/Smad signaling pathway, thereby promoting liver fibrosis | (7,60,98,99) |
|                               | • Exerts its effect by activating the TGF-β/Smad2 pathway while suppressing Smad7. |                                                                      |         |
| Hepatic ischemia-reperfusion injury (HIRI) | • Highly expressed in HIRI models. | • Serum TGF-β1 levels are upregulated in the HIRI mouse model.       | (45,100) |
|                               | • Promotes hepatocyte apoptosis through the TLR4-FADD pathway and inflammation through the NF-κB pathway. |                                                                      |         |
| Hepatocellular carcinoma (HCC) | • Highly expressed in HCC cells originating from cells with a high degree of motility. | • Limiting hepatocyte proliferation under normal conditions, but enabling chemically induced HCC in the heterozygous state. | (46,99,101-103) |
|                               | • Promotes HCC development through the ROS-JNK signaling pathway.       | • Promotes HCC progression and immune escape.                        |         |
| Chronic pancreatitis          | • Highly expressed in patients with CP. | • Highly expressed in a mouse model of CP. | (41,44,104) |
|                               | • Exerts its effect by activating the TGF-β/Smad2 signaling pathway and NF-κB signaling pathway. | • Promotes CP progression.                                           |         |
| Pancreatic cancer             | • Highly expressed in pancreatic cancer.                              | • Increased expression in patients with pancreatic ductal adenocarcinoma (PDAC). | (74,99,105) |
|                               | • Promotes the proliferation of PCCs, reduces apoptosis and promotes the invasion and migration of PCCs. | • Inhibition of TGF-β receptor inhibits tumor growth and metastasis. |         |
| Esophageal cancer             | • Highly expressed in ESCC.                                           | • Associated with the overall survival time in esophageal cancer.     | (79,99,106) |
|                               | • Promotes invasion and migration of esophageal squamous carcinoma cells. |                                                                      |         |
|                               | Could be used as a marker of lymph node metastasis in ESCC.             |                                                                      |         |
| Disease                  | Hic-5                                                                                   | TGF-β                                                                                   | (Refs.)                       |
|-------------------------|-----------------------------------------------------------------------------------------|-----------------------------------------------------------------------------------------|-------------------------------|
| Colorectal cancer       | • Highly expressed in the CAFs of patients with CRC.                                     | • Highly expressed in CRC.                                                               | (81,99,107,108)              |
|                         | • Promotes the expression of LOX, promotes the cross-linking of collagen fibers, and thus increases the stiffness of the ECM, ultimately promoting tumor progression. | • Inhibition of TGF-β signaling inhibits CRC metastasis                                |                               |
| Glomerulosclerosis      | • Increased expression in a rat model of glomerulosclerosis.                             | • Highly expressed in various kidney diseases associated with fibrosis.                 | (11,109,110)                 |
| Prostate cancer         | • Expressed in tumor prostate epithelium, AR-deficient prostate cancer cells, and in tissue from untreated stage IV prostate cancer. | • Inhibits proliferation in early stages of prostate cancer, promotes proliferation and metastasis in advanced stages. | (31,42,64, 111-113)         |
|                         | • Interacts with Smad 1 to inhibit apoptosis.                                            |                                                                                         |                               |
| Breast cancer           | • Increased expression in breast cancer cells.                                          | • TGF-β1 activated cancer-associated fibroblasts to promote breast cancer invasion, metastasis and EMT | (71,83,114)                  |
|                         | • Negatively associated with the DMFS of breast cancer patients.                        |                                                                                         |                               |
| Ovarian cancer          | • Highly expressed in ovarian cancer.                                                   | • Induces metastasis or EMT in advanced ovarian cancer                                   | (48,115)                     |
|                         | • Promotes EMT in ovarian cancer via RhoA/ROCK signaling.                                |                                                                                         |                               |
| Osteosarcoma            | • Highly expressed in the osteosarcoma.                                                 | • Serum levels are increased in patients with osteosarcoma.                             | (43,116,117)                 |
|                         | • Activates β-catenin by interacting with smad4 to promote osteosarcoma cell proliferation and inhibit osteosarcoma apoptosis. | • Promotes invasion and metastasis.                                                     | (84,118)                     |
| Melanoma                | • Expessed in human melanoma cells.                                                     | • Serum levels are increased in patients with AD.                                       | (85,119,120)                 |
|                         | • Promotes proliferation and migration.                                                 | • Reduce amyloid β-protein (Aβ) pathology of brain parenchyma.                           |                               |
| Alzheimer's disease     | • Increased expression in a rat model of AD                                             | • May be a useful biological marker for patients with AD.                               | (86,121)                     |
|                         |                                                                                         | • Serum levels are increased in patients with osteoarthritis.                            |                               |
|                         |                                                                                         | • Promotes osteoarthritis progression.                                                  |                               |
|                         |                                                                                         | • Elevated serum levels in patients with systemic sclerosis.                            | (90,122)                     |
| Osteoarthritis          | • Promotes the development of osteoarthritis by increasing the expression of MMP13 and ADAMTS5 | • Serum levels are increased in patients with osteoarthritis.                            |                               |
| Systemic sclerosis      | • Increased expression in systemic sclerosis skin.                                      | • Promotes osteoarthritis progression.                                                  |                               |

Hic-5, hydrogen peroxide-inducible clone 5; SMCs, smooth muscle cells; VSMCS, vascular smooth muscle cells; AAA, abdominal aortic aneurysm; EMT, epithelial-mesenchymal transition; TLR4, Toll-like receptor 4; FADD, Fas-associated protein with death domain; PCCs, pancreatic cancer cells; ESCC, esophageal squamous cell carcinoma; CRC, colorectal cancer; DMFS, distant metastasis-free survival; AD, Alzheimer's disease.
10. Conclusions

As an important component of focal adhesion sites, Hic-5 plays an essential role in cell proliferation, migration, differentiation and apoptosis. It also plays a key role in transcriptional regulation, as well as in the regulation of signaling pathways, and in the suppression of its functions can prevent the development of several diseases. Thus, Hic-5 may serve as a diagnostic biomarker, as well as a therapeutic target for a wide range of diseases, including tumors. Several studies have confirmed the expression of Hic-5 in various organs and its pathological roles in different systems; however, the exact physiological and pathological roles of Hic-5 in several other organs remain unclear and additional studies are required to explore its functions. The present review summarized the role of Hic-5 in a variety of organs and their associated diseases with the aim of providing an up-to-date background on the current body of literature from which future studies may be designed.

Acknowledgements

Not applicable.

Funding

The present study was supported by grants from the National Natural Science Foundation of China (grant nos. 81960507, 82073087 and 82160112), and the Collaborative Innovation Center of Chinese Ministry of Education (2020-39), the Science and Technology Bureau fund of Zunyi City [grant no. ZUN SHI KE HE HZ ZI (2019)93-Hao] and the Science and Technology Plan Project of Guizhou Province [grant nos. QIAN KE HE JI CHU-ZK (2021) YI BAN451 and QIAN KE HE LH ZI (2017)7095 HAO].

Availability of data and materials

Not applicable.

Authors’ contributions

SY and ZT drafted the manuscript and contributed equally. XY, LiZhang, YZ, LZheng and HW participated in the literature search and analysis of the data to be included in the review. ZY, JA and HJ were involved in the design of the study and assisted in the preparation of the figures and tables. GW and BT edited and revised the manuscript. All authors have read and approved the final version of the manuscript. Data authentication is not applicable.

Ethics approval and consent to participate

Not applicable.

Patient consent for publication

Not applicable.

Competing interests

The authors declare that they have no competing interests.

References

1. Shibanuma M, Mashimo J, Kuroki T and Nose K: Characterization of the TGF beta 1-inducible hic-5 gene that encodes a putative novel zinc finger protein and its possible involvement in cellular senescence. J Biol Chem 269: 26767-26774, 1994.
2. Shibanuma M, Mori K and Nose K: HIC-5: A mobile molecular scaffold regulating the anchorage dependence of cell growth. Int J Cell Biol 2012: 426138, 2012.
3. Kim-Kaneyama JR, Lei XF, Arita S, Miyazaki T and Miyazaki A: Hydrogen peroxide-inducible clone 5 (Hic-5) as a potential therapeutic target for vascular and other disorders. J Atheroscler Thromb 19: 601-607, 2012.
4. Yang L, Guerrero J, Hong H, DeFranco DB and Stallcup MR: Interaction of the tau2 transcriptional activation domain of glucocorticoid receptor with a novel steroid receptor coactivator, Hic-5, which localizes to both focal adhesions and the nuclear matrix. Mol Biol Cell 11: 2007-2018, 2000.
5. Kim-Kaneyama JR, Shibanuma M and Nose K: Transcriptional activation of the c-fos gene by a LIM protein, Hic-5. Biochem Biophys Res Comm 299: 360-365, 2002.
6. Shibanuma M, Kim-Kaneyama JR, Sato S and Nose K: A LIM protein, Hic-5, functions as a potential coactivator for Sp1. J Cell Biochem 91: 633-645, 2004.
7. Lei XF, Fu W, Kim-Kaneyama JR, Otomo T, Miyazaki T, Li B and Miyazaki A: Hic-5 deficiency attenuates the activation of hepatic stellate cells and liver fibrosis through upregulation of Smad7 in mice. J Hepatol 64: 110-117, 2016.
8. Matsuya M, Sasaki H, Aoto H, Mitaka T, Nagura K, Ohba T, Ishino M, Takahashi S, Suzuki R and Sasaki T: Cell adhesion kinase beta forms a complex with a new member, Hic-5, of proteins localized at focal adhesions. J Biol Chem 273: 1003-1014, 1998.
9. Nishiya N, Shirai T, Suzuki W and Nose K: Hic-5 interacts with GIT1 with a different binding mode from paxillin. J Biochem 132: 279-289, 2002.
10. Fujita H, Kamiguchi K, Cho D, Shibanuma M, Morimoto C and Tachibana K: Interaction of Hic-5, a senescence-related protein, with focal adhesion kinase. J Biol Chem 273: 26516-26521, 1998.
11. Horngold N, Craven RA, Keen JN, Johnson T, Banks RE and Mooney AF: Upregulation of Hic-5 in glomerulosclerosis and its regulation of mesangial cell apoptosis. Kidney Int 77: 329-338, 2010.
12. Mestayer C, Blanchère M, Jaubert F, Dufour B and Mowszowicz I: Expression of androgen receptor coactivators in normal and prostate tissues and cultured cell lines. Prostate 56: 192-200, 2003.
13. Kim-Kaneyama JR, Takeda N, Sasai A, Miyazaki A, Sata M, Hirabayashi T, Shibanuma M, Yamada G and Nose K: Hic-5 deficiency enhances mechano-sensitive apoptosis and modulates vascular remodeling. J Mol Cell Cardiol 50: 77-86, 2011.
14. Nishiya N, Ibawuchi Y, Shibanuma M, Côté JF, Tremblay ML and Nose K: Hic-5, a paxillin homologue, binds to the protein-tyrosine phosphatase beta (PTP-PEST) through its LIM 3 domain. J Biol Chem 274: 9847-9853, 1999.
15. López-Colomé AM, Lee-Rivera I, Benavides-Hidalgo R and López E: Paxillin: A crossroad in pathological cell migration. J Hematol Oncol 10: 50, 2017.
16. Ma X and Hammes SR: Paxillin actions in the nucleus. Steroids 133: 87-92, 2018.
17. Xu W, Alpha KM, Zuberbach NM and Turner CE: Paxillin promotes breast tumor collective cell invasion through maintenance of adhesion junction integrity. Mol Biol Cell 33: ar14, 2022.
18. Tanaka N, Minemura C, Asai S, Kikkawa N, Kinoshita T, Oshima S, Komai A, Kasamatsu A, Hanazawa T, Uzawa K and Seki N: Identification of miR-199-5p and miR-199-3p target genes: Paxillin facilitates cancer cell aggressiveness in head and neck squamous cell carcinoma. Genes (Basel) 12: 1910, 2021.
22. Mashimo J, Shibunuma M, Satoh H, Chida K and Nose K: Genomic structure and chromosomal mapping of the mouse hic-5 gene that encodes a focal adhesion protein. Gene 249: 99-103, 2000.

23. Panetti T, HW, Cogliati D, Caughey JP, Marcinkiewicz C, Huttenlocher A and Mosher DF: Extracellular matrix molecules regulate endothelial cell migration stimulated by lysophosphatidic acid. J Thromb Haemost 2: 1645-1656, 2004.

24. Hetey SE, Lalonde DP and Turner CE: Tyrosine-phosphorylated Hic-5 inhibits epithelial growth factor-induced lamellipodia formation with actin filaments. J Cell Sci 117: 1579-1590, 2004.

25. Tumbarello DA, Brown MC and Turner CE: The pillixin LD motifs. FEBS Lett 513: 114-118, 2002.

26. Brown MC and Turner CE: Paxillin: Adapting to change. Physiol Rev 84: 1315-1339, 2004.

27. Nishiya N, Tachibana K, Shibanuma M, Mashimo JI and Nose K: Hic-5 reduced cell spreading on fibronectin: Competitive effects between paxillin and Hic-5 through interaction with focal adhesion kinase. Mol Cell Biol 21: 5332-5345, 2001.

28. Shibunuma M, Kim-Kaneyama JR, Ishino K, Sakamoto N, Hishiki T, Yamaguchi K, Mori K, Mashimo J and Nose K: Hic-5 communicates between focal adhesions and the nucleus through oxidant-sensitive nuclear export signal. Mol Biol Cell 14: 1158-1171, 2003.

29. Heitzer MD and DeFranco DB: Hic-5, an adapter-like nuclear receptor coactivator. Nuc Recep Signal 4: e0109, 2006.

30. Chodankar R, Wu Y, Schiller BJ, Yamamoto KR and Heitzer M: Identification of Hic-5 as a focal adhesion protein. Gene 249: 99-103, 2000.

31. Heitzer M and DeFranco DB: Mechanism of action of Hic-5/ARA55, a LIM domain-containing nuclear receptor coactivator expressed in prostate stromal cells. Cancer Res 66: 7326-7333, 2006.

32. Ghogomu SM, van Veenrooij S, Rittmeier W, Wedlich D and Gradl D: Hic-5 is a novel repressor of lymphoid enhancer factor/ T-cel factor-driven transcription. J Biol Chem 281: 1755-1764, 2006.

33. Drori S, Giron GD, Tou L, Szwayn JD, Mueller E, Xia K, Shvidrasami RA and Spiegelman BM: Hic-5 regulates an epithelial-mesenchymal transition in ovarian cancer cells in a TGIF-independent manner. Oncogene 8: 8250-82530, 2017.

34. Yumimamochi T, Yatomi Y, Osada M, Ohmori T, Ishii Y, Nakazawa K, Hosogaya S and Ozaki Y: Expression of the LIM proteins paxillin and Hic-5 in human tissues. J Histochem Cytochem 51: 513-521, 2003.

35. Komorowsky C, Samarj S, Rehm M, Guidolin D and Gottel-Streube M: Hic-5 as a regulator of endothelial cell morphogenesis and connective tissue growth factor gene expression. J Mol Med (Berlin) 83: 623-631, 2005.

36. Pathak J, Aitken CA, Nurse P, Kelly CL, Lee HJ, Johnson GA and Bayless KJ: Hic-5 mediates the initiation of endothelial sprouting by regulating a key surface metalloproteinase. J Cell Sci 129: 743-756, 2016.

37. Nakazawa K, Hosogaya S and Ozaki Y: Expression of the LIM gene hic-5 in human tissues. J Histochem Cytochem 51: 513-521, 2003.

38. Kim-Kaneyama JR, Miyatake A, Lei XF, Arita S, Mino T, Takata N, Kou K, Eto K, Yoshida T, Miyazaki T, et al: Identification of Hic-5 as a novel regulatory factor for integrin αβ3 activation and platelet aggregation in mice. J Thromb Haemost 10: 1867-1874, 2012.

39. Miller RA, Bashir A, Steinberg D, Schulte ML, Jin C, et al: Identification of Hic-5 as a novel regulatory factor for integrin αβ3 activation and platelet aggregation in mice. J Cell Sci 130: 3764-3775, 2017.

40. Kim-Kaneyama JR, Wachi N, Sata M, Enomoto S, Fukabori K, Koh K, Shibunuma M and Nose K: Hic-5, an adaptor protein expressed in vascular smooth muscle cells, modulates the arterial response to injury in vivo. Biochem Biophys Res Commun 376: 682-687, 2008.

41. Vergallo R and Crea F: Atherosclerotic plaque healing. N Engl J Med 383: 846-857, 2020.

42. Almeida SO and Budoff M: Effect of statins on atherosclerotic plaque. Trends Cardiovasc Med 29: 451-455, 2019.

43. Arita-Okubo S, Kim-Kaneyama JR, Lei XF, Wu YG, Omishi K, Takata M, Miyazaki A, Miyazaki T and Miyazaki A: Role of Hic-5 in the formation of microvilli-like structures and the monocyte-endothelial interaction that accelerates atherosclerosis. Cardiovasc Res 105: 361-371, 2015.

44. Lund EE, Hill JA and Keller RS: Hic-5 is required for fetal gene expression and cytoskeletal organization of neonatal cardiac myocytes. J Mol Cell Cardiol 47: 520-527, 2009.

45. Ji Y, Ji Y, Li Z, Wang K, Zhang J, Lu J, Chen L, E Q, Zeng Y and Ji Y: Comparative proteomic analysis of rat hepatic stellate cell activation: A comprehensive view and suppressed immune response. Hepatology 56: 332-349, 2012.

46. Vege SS and Chari ST: Chronic pancreatitis. N Engl J Med 386: 869-878, 2022.

47. Jambha A, Kondo S, Urushihara M, Nagai T, Kim-Kaneyama JR, Takahashi T, Komai K, Hishiki T, Yamaguchi K and Nose K: Hic-5 regulates mesangial cell proliferation in proliferative glomerulonephritis in mice. PLoS One 10: e0122773, 2015.

48. Hornigold N and Mooney A: Extracellular matrix-induced Hic-5 regulates mesangial cell proliferation in proliferative glomerulonephritis in mice. PLoS One 10: e0122773, 2015.

49. Gao L, Qian B, Chen H, Wang A, Li Q, Li J, Tan P, Xia X, Du Y and Fu W: Hic-5 deficiency attenuates hepatic ischemia reperfusion injury through TLR4/NF-κB signaling pathways. Life Sci 219: 2299-2307, 2018.

50. Wu JR, Hu CT, You RI, Pan SM, Cheng CC, Lee MC, Wu CC, Chang YJ, Lin SC, Chen CS, et al: Hydrogen peroxide inducible clone-5 mediates reactive oxygen species signaling for hepatocellular carcinoma progression. Oncotarget 6: 32526-32534, 2015.

51. Tumbarello DA and Turner CE: Hic-5 contributes to epithelial-mesenchymal transition through a Rhoa/ROCK-dependent pathway. J Cell Physiol 211: 736-747, 2007.

52. Sheta R, Wang ZQ, Bacivarova M, Plante M, Gregoire J, Renaud MC, Sebastianelli A, Gobeli S, Morin C, Macdonald E, et al: Hic-5 regulates epithelial-to-mesenchymal transition in ovarian cancer cells in a TGIF-independent manner. Oncotarget 8: 82506-82530, 2017.
85. Caltagarone J, Hamilton RL, Murdoch G, Jing Z, DeFranco DB and Buchanan G: Hic-5 influences genomic and non-genomic actions of the androgen receptor in prostate myofibroblasts. Mol Cell Endocrinol 384: 185-199, 2014.

86. Miyauchi A, Kim-Kaneyama JR, Lei XF, Chang SH, Saito T, Goreczny GJ, Ouderkirk-Pecone JL, Olson Ec, Krendel M and Li P, Yu X, Ge K, Melamed J, Roeder RG and Wang Z: Heterogeneous expression and functions of androgen receptor co-factors in primary prostate cancer. Am J Pathol 161: 1467-1474, 2002.

87. Hanahan d: Hallmarks of cancer: New dimensions. cancer 75: 747-759, 2018.

88. Andersson P, Wu J, Wu J, Mao X, Xu J, Wang W, Liang c, Hua J, Liu J, Zhang B, Meng C, Yu X and Shi S: Crosstalk between cancer-associated fibroblasts and immune cells in the tumor microenvironment: New findings and future perspectives. Mol Cancer 20: 1, 2021.

89. Normolle dP, Leach dA, Buchanan G and deFranco dB: VD represses growth factor β-inducible gene Hic‑5 in systemic sclerosis skin and fibroblasts: A novel antifibrotic therapeutic target. Rheumatology (Oxford) 59: 3092-3098, 2020.

90. Reina-Torres E, De Ieso ML, Passuale LR, Madekurozwa M, van Batenburg-Sherwood J, Overby DR and Stamer WD: The vital role for nitric oxide in intraocular pressure homeostasis. Prog Retin Eye Res 83: 100922, 2021.

91. Nair KS, Srivastava C, Brown RV, Koli S, Choquet H, Kang HS, Kuo YM, Grimm SA, Sutherland C, Badea A, et al: GLIS1 regulates trabecular meshwork function and intraocular pressure and is associated with glaucoma in humans. Nat Commun 12: 4877, 2021.

92. Gough NR, Xiang X and Mishra L: TGF-β signaling in cancer: The TGF-β superfamily as a therapeutic target. Front Oncol 10: 873, 2020.

93. Reina-Torres E, De Ieso ML, Pasquale LR, Madekurozwa M, van Batenburg-Sherwood J, Overby DR and Stamer WD: The vital role for nitric oxide in intraocular pressure homeostasis. Prog Retin Eye Res 83: 100922, 2021.
107. Calon A, Lonardo E, Berenguer-Llergo A, Espinet E, Hernando-Momblona X, Iglesias M, Sevillano M, Palomo-Ponce S, Tauriello DV, Byrom D, et al: Stromal gene expression defines poor-prognosis subtypes in colorectal cancer. Nat Genet 47: 320-329, 2015.

108. Tauriello DV, Palomo-Ponce S, Stork D, Berenguer-Llergo A, Badia-Ramentol J, Iglesias M, Sevillano M, Ibiza S, Cañellas A, Hernando-Momblona X, et al: TGFβ drives immune evasion in genetically reconstituted colon cancer metastasis. Nature 554: 538-543, 2018.

109. Meng XM: Inflammatory mediators and renal fibrosis. Adv Exp Med Biol 1165: 381-406, 2019.

110. Gu YY, Liu XS, Huang XR, Yu XQ and Lan HY: TGF-β in kidney disease. Front Cell Dev Biol 8: 123, 2020.

111. Wang H, Song K, Krebs TL, Yang J and Danielpour D: Smad7 is inactivated through a direct physical interaction with the LIM protein Hic-5/ARA55. Oncogene 27: 6791-6805, 2008.

112. Thompson-Elliott B, Johnson R and Khan SA: Alterations in TGF-β signaling during prostate cancer progression. Am J Clin Exp Urol 9: 318-328, 2021.

113. Miyauchi S, Paskeh MD, Saghari Y, Zarrabi A, Hamblin MR, Entezari M, Hashemi M, Aref AR, Hushmandi K, Kumar AP, et al: Transforming growth factor-beta (TGF-β) in prostate cancer: A dual function mediator? Int J Biol Macromol 206: 435-452, 2022.

114. Huang M, Fu M, Wang J, Xia C, Zhang H, Xiong Y, He J, Liu J, Liu B, Pan S and Liu F: TGF-β1-activated cancer-associated fibroblasts promote breast cancer invasion, metastasis and epithelial-mesenchymal transition by autophagy or overexpression of FAP-α. Biochem Pharmacol 188: 114527, 2021.

115. Roane BM, Arend RC and Birrer MJ: Review: Targeting the transforming growth factor-beta pathway in ovarian cancer. Cancers (Basel) 11: 668, 2019.

116. Lamora A, Talbot J, Bougras G, Amiaud J, Leduc M, Chesneau J, Taurelle J, Stresing V, Le Deley MC, Heymann MF, et al: Overexpression of smad7 blocks primary tumor growth and lung metastasis development in osteosarcoma. Clin Cancer Res 20: 5097-5112, 2014.

117. Xu S, Yang S, Sun G, Huang W and Zhang Y: Transforming growth factor-beta polymorphisms and serum level in the development of osteosarcoma. DNA Cell Biol 33: 802-806, 2014.

118. Bu MT, Chandrasekhar P, Ding L and Hugo W: The roles of TGF-β and VEGF pathways in the suppression of antitumor immunity in melanoma and other solid tumors. Pharmacol Ther 240: 108211, 2022 (Epub ahead of print).

119. Zheng C, Zhou XW and Wang JZ: The dual roles of cytokines in Alzheimer's disease: Update on interleukins, TNF-α, TGF-β and IFN-γ. Transl Neurodegener 5: 7, 2016.

120. Park JK, Lee KJ, Kim JY and Kim H: The association of blood-based inflammatory factors IL-β, TGF-β and CRP with cognitive function in Alzheimer's disease and mild cognitive impairment. Psychiatry Investig 18: 11-18, 2021.

121. van der Kraan PM: The changing role of TGFβ in healthy, ageing and osteoarthritic joints. Nat Rev Rheumatol 13: 155-163, 2017.

122. Kuźnik-Trocha K, Winsz-Szczotka K, Komosińska-Vassey K, Jura-Półtorak A, Kotulska-Kucharz A, Kucharz EJ, Kotyla P and Olczyk K: Plasma glycosaminoglycan profiles in systemic sclerosis: Associations with MMP-3, MMP-10, TIMP-1, TIMP-2, and TGF-beta. Biomed Res Int 2020: 6416514, 2020.

123. Wu WS, Ling CH, Lee MC, Cheng CC, Chen RF, Lin CF, You RI and Chen YC: Targeting Src-Hic-5 signal cascade for preventing migration of cholangiocarcinoma cell HuCCT1. Biomedicines 10: 1022, 2022.

This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International (CC BY-NC 4.0) License.